Venn Life Sciences Holdings PLC Directorate Update (3757D)
25 June 2019 - 10:24PM
UK Regulatory
TIDMVENN
RNS Number : 3757D
Venn Life Sciences Holdings PLC
25 June 2019
25 June 2019
Venn Life Sciences Holdings Plc
("Venn Life Sciences" or the "Company")
Directorate Update
The Board has made excellent progress in selecting a further
independent non-executive director. An appointment is expected by
the end of August 2019. Following further consideration of the
Board composition, the Board has concluded that Brendan Buckley
will no longer be considered an "independent director" with respect
to the Company's application of the QCA Code. The Board reiterates
its view that Brendan Buckley is of independent character and
judgement and will play a key role in the development of Venn Life
Sciences from his position as Chairman. Additionally, reference to
"UK Corporate Governance Code" on page 23 of the Admission Document
refers to the QCA Code.
The Board is committed to upholding the highest standards of
corporate governance. Further detail of the Board's approach to
corporate governance is available on the Company's website at www.
vennlifesciences.com/investors/.
Enquiries:
Venn Life Sciences Holdings Plc Tel: +353 1 5499 341
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
About Venn Life Sciences
Venn Life Sciences is an Integrated Drug Development Partner
offering a combination of drug development expertise and clinical
trial design and management to pharmaceutical, biotechnology and
medical device organisations. Venn Life Sciences has dedicated
operations in France, Germany, the Netherlands, the UK and Ireland
with partners across Europe and the US.
Further information in relation to Venn Life Sciences
www.Vennlifesciences.com
Venn Life Sciences: getintouch@Vennlife.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOABDGDLDDDBGCU
(END) Dow Jones Newswires
June 25, 2019 08:24 ET (12:24 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024